Glutathione: What the Bioavailability Data Actually Show

Glutathione is a tripeptide (glutamate-cysteine-glycine) and the body's main intracellular antioxidant. Evidence level is moderate overall and route-dependent: plain oral glutathione has negligible systemic availability after a single dose, liposomal and sublingual forms do raise blood and cell levels, IV dosing produces very high plasma levels with a half-life of about 14 minutes, and inhaled delivery reaches the lungs but failed its cystic fibrosis trial. The clearest randomised outcome data are for IV glutathione preventing cisplatin neuropathy. Clinical doses run 600 to 2,000 mg IV, 250 to 1,000 mg/day liposomal oral, and 200 to 600 mg nebulised. Compounded injectable glutathione has triggered repeated FDA endotoxin alerts.

Glutathione is the main antioxidant your cells make themselves. Swallowing it as a plain capsule mostly does not work: the gut takes it apart. Fat-coated (liposomal) capsules, sublingual tablets and drips do raise levels. Nebulisers put it into the lungs. Raising the level is easy to measure; proving it makes people better is harder, and only a few conditions have good trial evidence.

Glutathione: What the Bioavailability Data Actually Show

At a Glance

Feature	Detail
Full name / class	Glutathione (GSH), the tripeptide γ-glutamyl-cysteinyl-glycine
Origin	Endogenous; synthesised in every cell, highest concentrations in the liver
Mechanism	Direct scavenging of reactive oxygen species, phase II conjugation of toxins, recycling of vitamins C and E, redox regulation
Used for	Oxidative-stress conditions, detoxification protocols, Parkinson’s disease, liver disease, chemotherapy neuropathy, skin brightening
Routes	IV, IM, nebulised, intranasal, oral (plain, liposomal, sublingual, S-acetyl)
Typical dose range	IV 600–2,000 mg 1–3×/week; oral liposomal 250–1,000 mg/day; nebulised 200–600 mg 1–2×/day
Evidence level	Moderate: good human pharmacokinetic and biomarker data; randomised outcome evidence is positive for cisplatin neuropathy, negative in cystic fibrosis, and not superior to placebo in Parkinson’s disease
Regulatory status	Licensed injectable medicine in Italy and some other countries for cisplatin neuropathy prophylaxis; in the US a dietary supplement orally and a compounded injectable with repeated FDA endotoxin alerts; not on the WADA list

Glutathione is the most-infused substance in integrative medicine and one of the easiest to argue about, because almost everyone discussing it merges two separate questions: does a route raise glutathione levels, and does raising glutathione levels help anyone? The first has clear answers. The second has answers for a few specific conditions and not for the rest.

The honest summary: route matters enormously, the pharmacokinetics are short, the biomarker effects are real, and outcome evidence is thin except in chemotherapy-induced neuropathy. The issue that deserves more attention than the efficacy debate is the quality of compounded injectable product.

This article covers the pharmacology across routes. For the clinical IV protocol as used in practice, see the IV glutathione therapy guide; for the precursor route, see NAC versus glutathione.

How It Works

Glutathione is made inside cells from glutamate, cysteine and glycine, with cysteine as the rate-limiting ingredient. Its jobs:

Direct antioxidant. It reduces hydrogen peroxide and lipid peroxides through glutathione peroxidase, becoming oxidised glutathione (GSSG) and then being recycled by glutathione reductase. The GSH/GSSG ratio is the standard laboratory index of cellular redox state.
Detoxification. Glutathione S-transferases conjugate glutathione to electrophiles, including heavy metal species and drug metabolites, making them water-soluble and excretable. This is the mechanism behind N-acetylcysteine use in paracetamol poisoning.
Cofactor recycling. It regenerates vitamins C and E.
Cysteine delivery. This is the underappreciated part. After IV infusion, plasma cysteine rises steeply, from about 8.9 to 114 micromol/L [1], so part of what is attributed to glutathione may come from supplying cysteine to cells that then make their own.

The practical limit follows from the chemistry. Glutathione does not readily cross cell membranes intact; it is largely broken down at the cell surface and resynthesised inside. Raising plasma glutathione is not the same as raising it inside a neuron.

What the Evidence Shows: Route by Route

Intravenous

Pharmacokinetics (Aebi 1991, 10 healthy volunteers). After 2 g/m² IV, plasma total glutathione rose from 17.5 to 823 micromol/L. Volume of distribution was about 176 mL/kg and the elimination half-life about 14 minutes. Plasma cysteine rose to 114 micromol/L [1].
Cisplatin neuropathy (Cascinu 1995, randomised, double-blind, placebo-controlled). Glutathione during cisplatin chemotherapy for advanced gastric cancer: at week 9 no patient in the glutathione arm had clinically evident neuropathy versus 16 in the placebo arm; by week 15, 4 of 24 assessable glutathione patients versus 16 of 18 placebo patients had neurotoxicity (P = 0.0001), confirmed on sensory nerve conduction studies [2]. This is the strongest randomised outcome evidence for parenteral glutathione and the basis for its Italian product licence.
Parkinson’s disease (Hauser 2009, n = 21). IV glutathione 1,400 mg three times weekly for 4 weeks versus placebo. Well tolerated, no withdrawals for adverse events, and no significant difference in UPDRS scores [3].
Non-alcoholic fatty liver disease (Honda 2017, 34 enrolled, 29 completed). An open-label, single-arm trial of glutathione 300 mg/day for 4 months after a 3-month lifestyle run-in: ALT, triglycerides, non-esterified fatty acids and ferritin fell [4]. Single-arm, so neither the lifestyle intervention nor regression to the mean is controlled for.

Oral

Plain oral, single dose (Witschi 1992, n = 7). After 0.15 mmol/kg, plasma glutathione, cysteine and glutamate did not rise significantly over 270 minutes. The authors concluded systemic availability is negligible in man because of hydrolysis by intestinal and hepatic gamma-glutamyltransferase [5].
Plain oral, 6 months (Richie 2015, n = 54, randomised, double-blind, placebo-controlled). 250 or 1,000 mg/day. At 6 months glutathione rose 30–35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells on the high dose, and 17% in blood and 29% in erythrocytes on the low dose. The oxidised-to-reduced ratio fell and natural killer cell cytotoxicity increased. Levels returned to baseline after a 1-month washout [6]. Chronic dosing therefore does something a single dose does not, probably by supplying cysteine.
Plain oral, 4 weeks (Allen 2011, 40 randomised, 39 completed per protocol). No significant change in F2-isoprostanes, 8-OHdG or any measure of glutathione status [7]. Two randomised trials, opposite results, differing in dose and duration.
Liposomal (Sinha 2018, n = 12, open pilot). 500 or 1,000 mg/day for one month. By two weeks: whole blood glutathione up 40%, erythrocytes 25%, plasma 28%, peripheral blood mononuclear cells 100%; plasma 8-isoprostane down 35%; natural killer cell cytotoxicity up to 400% higher and lymphocyte proliferation up to 60% higher [8]. Small and uncontrolled, but the fastest rise in measured levels of any oral form.
Sublingual (Schmitt 2015, n = 20 with metabolic syndrome, randomised crossover). Sublingual glutathione beat both plain oral glutathione and NAC on total and reduced plasma glutathione and the GSH/GSSG ratio (P = 0.003), and raised plasma vitamin E [9].

Nebulised and intranasal

Cystic fibrosis (Griese 2013, n = 153, randomised, double-blind, placebo-controlled). 646 mg inhaled glutathione in 4 mL every 12 hours for 6 months via an investigational eFlow nebuliser. The primary endpoint, FEV1, did not differ from placebo. Glutathione and its metabolites did rise in sputum, confirming delivery to the lungs, but with no change in markers of oxidation, proteolysis or inflammation, no fewer exacerbations and no better quality of life [10]. Delivery was proven; benefit was not.
Asthma safety signal (Marrades 1997, n = 8, randomised, double-blind, crossover). 600 mg nebulised glutathione caused major airway narrowing: FEV1 fell 19% and total pulmonary resistance rose 61%, with cough in four and breathlessness in three of eight patients with mild asthma. Osmolarity and pH did not explain it [11]. The accepted explanation is sulfite generation; a review of inhaled glutathione recommends urine sulfite testing before treatment and considers it contraindicated when positive [12].
Intranasal in Parkinson’s disease. A phase I/IIa trial (n = 30) of 300 or 600 mg/day in three divided doses for 3 months found no substantial differences between groups in adverse events or tolerability [13]. Magnetic resonance spectroscopy in 15 patients showed that a single 200 mg intranasal dose raised brain glutathione [14]. The phase IIb trial (n = 45; placebo versus 100 mg or 200 mg three times daily for 3 months) found all groups improved, including placebo; the high-dose group improved on the total UPDRS (-4.6 points, P = 0.0025) and the motor subscore, but neither treatment group beat placebo, and one high-dose participant developed cardiomyopathy [15].
Patient-reported survey (Mischley 2013, n = 70, 23.3% response rate). Among patients prescribed intranasal glutathione, 78.8% reported an overall positive experience, 62.1% reported health benefits and 12.1% reported adverse effects [16]. A low-response-rate survey of prescribed patients is the weakest design that still counts as data.

Skin brightening

A dermatology review concluded that evidence for glutathione as a skin-whitening agent is limited and that IV use for this purpose lacks adequate safety and efficacy data [17]. Several national regulators have warned against high-dose IV use for cosmetic skin lightening.

What is missing

Head-to-head comparisons of routes with the same outcome, and randomised outcome trials outside oncology. Almost every positive result outside cisplatin neuropathy is a biomarker change, an uncontrolled trial or a survey.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Goal	Dose	Route	Frequency / timing	Cycle length	Basis
Cisplatin neuropathy prophylaxis	1.5 g/m² (about 2.5 g)	Slow IV infusion, 15–30 min before chemotherapy	Each chemotherapy cycle	Per chemotherapy course	Label (Italian SmPC for glutathione 600 mg / 2,500 mg injection) / Trial [2]
Longer chemotherapy courses	600 mg	IM or slow IV	Per protocol	Per course	Label (Italian SmPC)
Parkinson’s disease, IV trial	1,400 mg	IV	3× weekly	4 weeks (no benefit over placebo)	Trial [3]
Parkinson’s disease, intranasal trial	100 mg or 200 mg	Intranasal	Three times daily	3 months (not superior to placebo)	Trial [15]
Clinical IV push (practice)	600–2,000 mg	IV push over 5–15 min	1–3× weekly for loading, then weekly or every two weeks	4–6 weeks loading, then maintenance	Practice protocol (Karpa Health clinical guide; see the IV glutathione guide)
IM injection (practice)	200–600 mg	IM	2–3× weekly	Ongoing with breaks	Practice protocol (Karpa Health)
Oral maintenance, liposomal	250–1,000 mg/day	Oral liposomal	Once or twice daily	Continuous; levels return to baseline about a month after stopping [6]	Trial [6][8]
Oral, sublingual	Per product, typically 50–300 mg	Sublingual	Daily	3 weeks in the trial	Trial [9]
Nebulised, pulmonary (practice)	200–300 mg in 4–5 mL saline, titrated up to 600 mg	Nebuliser, 5–10 min	1–2× daily	While symptomatic	Practice protocol (Integrative Medicine Center of Western Colorado; Karpa Health)
Nebulised, study doses	600 mg once or twice daily, up to 1,350 mg/day; 646 mg twice daily in the CF trial	Nebuliser	Daily	Per study	Trial [10]; review of study doses [12]
Cofactor stack	NAC 600–1,800 mg/day; alpha-lipoic acid 300–600 mg/day; glycine; selenium within the reference range	Oral	Daily	Ongoing	Practice protocol (Karpa Health; see NAC vs glutathione)

Practical points:

Infusion rate. A fast IV push, under 5 minutes, is the usual reason for the sulfur smell, flushing, chest tightness or nausea. Slower administration avoids most of it.
Test dose before nebulising. Given the asthma data [11], the standard precaution is a small test dose with spirometry or peak-flow readings before and after, and avoiding it altogether in sulfite-sensitive patients [12].
Plain oral capsules are the weakest route for a fast effect. If someone is taking oral glutathione, liposomal and sublingual forms have the better bioavailability data [8][9].
Chemotherapy interaction. Avoid during platinum-based chemotherapy unless an oncologist has prescribed it for neuropathy prophylaxis on the trial schedule, because of the theoretical concern about reducing drug efficacy.
Injection technique and reconstitution: see the peptide injection guide.

What People Report: What Works and What Doesn’t

Glutathione has the largest user base of anything in this library, spread across IV clinics, long-COVID forums and skincare communities. The patterns below come from the published patient survey [16] and user threads.

Reported to work

Mental clarity, often described as the earliest effect, within the first one to three IV sessions. This is also the most placebo-prone outcome in an infusion setting.
Intranasal use for multiple chemical sensitivity, sinus symptoms and allergies: in the published survey these were the commonest prescribing reasons, and 62% of respondents reported benefit [16].
Skin brightening and more even tone after repeated IV sessions, described consistently in skincare communities (r/IndianSkincareAddicts). The dermatology literature does not support IV use for this purpose [17].
Recovery and sleep benefits from S-acetyl or liposomal oral forms (r/Supplements).

Mixed or unclear

Long-COVID users report both clear improvement and nothing at all from liposomal glutathione (r/covidlonghaulers).
Whether IV beats oral liposomal for a given person. Community opinion splits and no head-to-head trial exists (r/glutathione).

Reported not to work, or disappointing

“It did nothing for me” is a common verdict for oral forms (r/Supplements).
Side effects described: sulfur taste or smell, bloating and loose stools at higher oral or IV doses, painful injections (r/NooTopics), and an unwanted yellow-grey skin tone after aggressive cosmetic IV courses.

What a proper trial would need to show: in a defined population such as long-COVID fatigue, a blinded comparison of liposomal glutathione, IV glutathione and placebo infusion, measuring both glutathione levels and a patient-centred primary outcome, long enough to separate the infusion ritual from the molecule.

Safety and Side Effects

IV: transient sulfur taste or odour, flushing, chest tightness and nausea with fast pushes; bloating and loose stools at higher doses; injection-site discomfort with IM use. Prolonged high-dose IV protocols may deplete zinc, which is worth monitoring.
Nebulised: cough and an unpleasant odour are common and mild. Bronchoconstriction is the serious risk, demonstrated at 600 mg in mild asthma [11], and most likely in sulfite-sensitive people [12].
Intranasal: generally well tolerated in trials [13]; one participant on high-dose intranasal glutathione in the phase IIb study developed cardiomyopathy, reported by the authors without a causal claim [15].
Contraindications and cautions: sulfite sensitivity, especially for inhalation; asthma and reactive airway disease (test dose first); active platinum-based chemotherapy unless the oncologist prescribes it; pregnancy and breastfeeding, where there is no data for these routes.
Product risk, the most important practical point. Compounded injectable glutathione has repeatedly failed on endotoxin. In February 2019 FDA warned compounders not to use one supplier’s glutathione powder after seven patients had reactions ranging from nausea and vomiting to difficulty breathing, with one hospitalisation, and said high endotoxin levels may have contributed; the powder had gone to around 100 compounders in 30 states [18]. In August 2026 FDA reported at least 30 patients with fever, chills, pain, dizziness, shock-like and sepsis-like reactions after IV glutathione compounded from dietary-supplement-grade material, with two Texas pharmacies recalling product for elevated endotoxin. FDA’s position is explicit: dietary-supplement-grade ingredients are not appropriate for injectable drugs, and compounders should not rely on testing alone [19].

That is the risk to weigh. The molecule is benign; the supply chain is not reliably so.

Legal and Regulatory Status

US: Oral glutathione is sold as a dietary supplement. There is no FDA-approved glutathione injection, so every IV, IM or nebulised dose comes from a compounding pharmacy, and FDA has issued repeated warnings about the ingredient grade used for those preparations [18][19]. Glutathione does not appear on FDA’s 503A category 1 or category 2 peptide lists; the enforcement issue has been ingredient quality rather than the substance itself.
EU: Injectable glutathione holds national marketing authorisations in some member states, including Italy, where the licensed indication is prophylaxis of neuropathy from cisplatin and related chemotherapy, at 1.5 g/m² or 600 mg per dose. There is no authorised nebulised or intranasal product.
Germany: Glutathione injections are not a standard authorised product; parenteral use for the purposes described here would be a pharmacy preparation or an import on prescription, and oral products are regulated as food supplements.
Cosmetic use: several Asian regulators, including the Philippine FDA, have issued public warnings against high-dose IV glutathione for skin whitening.
Sport: glutathione is not named on the WADA 2026 Prohibited List. The infusion rule applies: intravenous infusions of more than 100 mL per 12 hours are prohibited under M2.2 outside hospital treatment, surgical procedures or clinical investigation, so a diluted drip can breach the rules even though the substance does not.

How the Routes Compare

Route	Raises measured glutathione?	Outcome evidence	Main drawback
IV	Yes, dramatically; half-life about 14 min [1]	Positive for cisplatin neuropathy [2]; negative in Parkinson’s [3]	Short-lived; compounding quality and endotoxin risk [18][19]
Oral, plain	Not after a single dose [5]; yes after 6 months [6]	None	Slow, and one randomised trial found no biomarker change [7]
Oral, liposomal	Yes, within 1–2 weeks [8]	None (biomarkers only)	Small uncontrolled data; product variability
Sublingual	Yes, better than plain oral and NAC [9]	None	One small crossover trial
Nebulised	Yes, in sputum [10]	Negative in cystic fibrosis [10]	Bronchoconstriction risk [11]
Intranasal	Yes, in brain on MR spectroscopy [14]	Not superior to placebo in Parkinson’s [15]	Thin data outside Parkinson’s

If the goal is simply to raise glutathione reliably with the best safety profile, NAC plus glycine orally, or a liposomal or sublingual glutathione product, achieves it without a needle. If the goal is a specific clinical indication, the evidence narrows to chemotherapy neuropathy.

Frequently asked questions

Is oral glutathione absorbed?

Plain oral glutathione is largely not absorbed intact. A 1992 pharmacokinetic study of a single 0.15 mmol/kg dose found no significant rise in plasma glutathione, cysteine or glutamate, because intestinal and hepatic gamma-glutamyltransferase breaks it down. A 6-month randomised trial of 250 or 1,000 mg daily did raise body stores, so long-term daily dosing behaves differently from a single dose.

Does liposomal glutathione work better?

It raises measured levels faster. A one-month study of 500 or 1,000 mg daily of liposomal glutathione found whole blood up 40% and glutathione in peripheral blood mononuclear cells up 100% by two weeks, with lower oxidative stress markers and higher natural killer cell cytotoxicity. It was a small, open pilot in 12 subjects, not an outcome trial.

How long does IV glutathione stay in the blood?

Not long. After a 2 g/m2 infusion in healthy volunteers, plasma total glutathione rose from about 17.5 to 823 micromol/L and the elimination half-life was about 14 minutes. Much of the rationale rests on delivering cysteine equivalents rather than on sustained glutathione levels.

What dose of IV glutathione is used?

Clinical practice protocols use 600 to 2,000 mg as an IV push over 5 to 15 minutes, one to three times weekly. The oncology label dose for preventing cisplatin neuropathy is 1.5 g/m2 before chemotherapy, with 600 mg intramuscular or slow IV doses in longer courses.

Is nebulised glutathione safe?

It carries a specific risk. In a randomised crossover study in eight patients with mild asthma, 600 mg nebulised glutathione caused major airway narrowing, with FEV1 falling 19% and cough or breathlessness in most participants. Review authors recommend testing urine for sulfites first and avoiding it in sulfite-sensitive patients.

Is compounded IV glutathione risky?

The FDA has issued repeated alerts. In 2019 it warned compounders not to use one supplier's glutathione powder after seven adverse events, and in August 2026 it reported at least 30 patients with fever, chills, shock-like or sepsis-like reactions after IV glutathione compounded from dietary-supplement-grade material, consistent with excessive endotoxin.

Physician-written. Written by a practicing physician at St. George Hospital. Educational content, not individual medical advice.

References

Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991;21(1):103-110. https://pubmed.ncbi.nlm.nih.gov/1907548/
Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13(1):26-32. https://pubmed.ncbi.nlm.nih.gov/7799029/
Hauser RA, Lyons KE, McClain T, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24(7):979-983. https://pubmed.ncbi.nlm.nih.gov/19230029/
Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17(1):96. https://pubmed.ncbi.nlm.nih.gov/28789631/
Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669. https://pubmed.ncbi.nlm.nih.gov/1362956/
Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. https://pubmed.ncbi.nlm.nih.gov/24791752/
Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-833. https://pubmed.ncbi.nlm.nih.gov/21875351/
Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72(1):105-111. https://pubmed.ncbi.nlm.nih.gov/28853742/
Schmitt B, Vicenzi M, Garrel C, Denis FM. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol. 2015;6:198-205. https://pubmed.ncbi.nlm.nih.gov/26262996/
Griese M, Kappler M, Eismann C, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 2013;188(1):83-89. https://pubmed.ncbi.nlm.nih.gov/23631796/
Marrades RM, Roca J, Barberà JA, et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med. 1997;156(2 Pt 1):425-430. https://pubmed.ncbi.nlm.nih.gov/9279219/
Prousky J. The treatment of pulmonary diseases and respiratory-related conditions with inhaled (nebulized or aerosolized) glutathione. Evid Based Complement Alternat Med. 2008;5(1):27-35. https://pubmed.ncbi.nlm.nih.gov/18317545/
Mischley LK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Mov Disord. 2015;30(12):1696-1701. https://pubmed.ncbi.nlm.nih.gov/26230671/
Mischley LK, Conley KE, Shankland EG, et al. Central nervous system uptake of intranasal glutathione in Parkinson’s disease. NPJ Parkinsons Dis. 2016;2:16002. https://pubmed.ncbi.nlm.nih.gov/28725693/
Mischley LK, Lau RC, Shankland EG, et al. Phase IIb study of intranasal glutathione in Parkinson’s disease. J Parkinsons Dis. 2017;7(2):289-299. https://pubmed.ncbi.nlm.nih.gov/28436395/
Mischley LK, Vespignani MF, Finnell JS. Safety survey of intranasal glutathione. J Altern Complement Med. 2013;19(5):459-463. https://pubmed.ncbi.nlm.nih.gov/23240940/
Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82(3):262-272. https://pubmed.ncbi.nlm.nih.gov/27088927/
U.S. Food and Drug Administration. FDA warns compounders not to use glutathione from Letco Medical to compound sterile drugs. February 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-compounders-not-use-glutathione-letco-medical-compound-sterile-drugs
U.S. Food and Drug Administration. FDA reminds compounders not to use dietary supplement grade glutathione in injectables. Content current as of 27 August 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables

Glutathione: What the Bioavailability Data Actually Show

At a Glance

How It Works